Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440743 | 1.00 | GPR3 (0.41) | GPR3 | |
| SCHEMBL8152542 | 0.98 | GPR3 (0.39) | GPR3 | |
| SCHEMBL2020045 | 0.95 | GPR3 (0.41) | GPR3 | |
| SCHEMBL19428099 | 0.95 | GPR3 (0.41) | GPR3 | |
| SCHEMBL17441018 | 0.95 | GPR3 (0.41) | GPR3 | |
| SCHEMBL31091548 | 0.80 | GPR3 (0.37) | GPR3 | |
| SCHEMBL15357241 | 0.80 | GPR3 (0.37) | GPR3 | |
| SCHEMBL8281426 | 0.80 | GPR3 (0.37) | GPR3 | |
| SCHEMBL13539997 | 0.79 | KDM4E (0.37) | GPR3 | |
| SCHEMBL18731611 | 0.79 | GPR3 (0.36) | GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109219609-B | Fused hexacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3436456-B1 | FUSED HEXACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2021-11-17 | — | — | EP | disclosed |
| US-10766906-B2 | Fused hexacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2020-09-08 | — | — | US | disclosed |
| US-10766906-B2 | Fused hexacyclic imidazole derivatives as modulators of TNF activity | UCB Biopharma SRL (BE) | 2020-09-08 | — | — | US | disclosed |
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190100526-A1 | Fused Hexacyclic Imidazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2019-04-04 | — | — | US | disclosed |
| US-20190100526-A1 | Fused Hexacyclic Imidazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2019-04-04 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100526-A1 | Fused Hexacyclic Imidazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | GPR3 1760/4885 |
| US-10246456-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | GPR3 2474/4885 |
| US-10766906-B2 | Fused hexacyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | GPR3 2879/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | GPR3 2474/4885 |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | GPR3 2594/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | GPR3 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.